How should an investor evaluate a single-asset biotech operating in the Lung Cancer Therapeutics Market?

Assess whether the asset addresses a resistance mechanism created by an incumbent therapy. Those positions attract acquirers because the patient pool grows automatically. Single assets without a resistance or combination angle rarely command premium multiples [21]. Read More

What contracting terms are becoming standard in oncology drug procurement?

Outcomes-based agreements tying rebate levels to progression-free survival now appear routinely in European and US payer contracts. Hospitals should negotiate biomarker-testing support as a separate deliverable rather than accepting bundled marketing programmes [7][13]. Read More

How do bispecific engagers compare operationally with checkpoint inhibitors?

Bispecifics require step-up dosing and cytokine release syndrome monitoring, often mandating inpatient observation for initial cycles. That infrastructure burden restricts early adoption to centres with existing cellular therapy capability [4]. Read More

What regulatory nuance most affects launch timing in the Lung Cancer Therapeutics Market?

Accelerated approvals now carry stricter confirmatory trial enrolment requirements, with regulators expecting the trial underway at the time of accelerated clearance. Sponsors who delay confirmatory recruitment face withdrawal risk [4][5]. Read More

Which integration challenge slows adoption of precision regimens most?

Turnaround time on tissue-based sequencing. Community sites frequently wait two to three weeks for results, during which clinicians start chemotherapy. Liquid biopsy shortens that window but carries lower sensitivity for fusion detection [8]. Read More

Is there an emerging use case beyond metastatic treatment worth tracking?

Minimal residual disease monitoring after curative surgery. Circulating tumour DNA detection is being tested to select patients for adjuvant escalation, which would create a treatment decision point that does not currently exist commercially [9][11]. Read More

How does biosimilar entry reshape competitive dynamics in the Lung Cancer Therapeutics Market?

Originators typically defend through subcutaneous reformulation, fixed-dose combinations and device-linked presentations rather than price. Buyers should expect list-price stability alongside deeper confidential rebates during the first two years of competition [19][20]. Read More

Lung Cancer Market (2026 - 2035)

Lung Cancer Market Research Report: Size, Share, Trend Analysis By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Diagnosis Type (Imaging Tests, Biopsy, Sputum Cytology, Blood Tests), By Patient Demographics (Age, Gender, Smoking History, Geographic Location), By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

11.5%

2025 Market Size

USD 29.84 Billion

2035 Market Size

USD 89.22 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/0679-CR | Pages: 200 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Disease Type & Treatment Modality |
2. 2.2 By Drug Class & Distribution Channel |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Immuno-Oncology and Bispecific Engagers |
2. 4.2 Biomarker Testing Penetration |
3. 4.3 Regulatory Acceleration and Project Orbis |
4. 4.4 Lung Screening Programme Expansion
5 Restraints Impact Analysis |
1. 5.1 Payer Price Pressure and Value-Based Contracting |
2. 5.2 Patent Expiry and Biosimilar Erosion |
3. 5.3 Acquired Resistance and Treatment Duration Limits
6 Opportunity Analysis |
1. 6.1 Perioperative and Early-Stage Treatment |
2. 6.2 Antibody-Drug Conjugates in Biomarker-Undefined Populations |
3. 6.3 Emerging-Market Access and Tiered Pricing |
4. 6.4 Diagnostics-Linked Business Models |
5. 6.5 Resistance-Directed Sequencing Portfolios
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Machine Learning in Patient Selection |
2. 8.2 Combination Platforms as the Competitive Unit |
3. 8.3 Biosimilar Transition in Checkpoint Inhibition |
4. 8.4 Prevention Economics and Tobacco Policy
9 Market Segmentation Analysis |
1. 9.1 By Disease Type | |
  1. 9.1.1 Non-Small Cell Lung Cancer | |
  2. 9.1.2 Small Cell Lung Cancer | |
  3. 9.1.3 Others |
2. 9.2 By Treatment Modality | |
  1. 9.2.1 Chemotherapy | |
  2. 9.2.2 Immunotherapy | |
  3. 9.2.3 Targeted Therapy | |
  4. 9.2.4 Others |
3. 9.3 By Drug Class | |
  1. 9.3.1 Small-Molecule Drugs | |
  2. 9.3.2 Biologics and Biosimilars |
4. 9.4 By Distribution Channel | |
  1. 9.4.1 Hospital Pharmacies | |
  2. 9.4.2 Retail Pharmacies | |
  3. 9.4.3 Online / Specialty Pharmacies |
5. 9.5 By Line of Therapy | |
  1. 9.5.1 First-Line | |
  2. 9.5.2 Second-Line | |
  3. 9.5.3 Third-Line and Later
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 AstraZeneca | |
  2. 10.3.2 Merck & Co. | |
  3. 10.3.3 Roche / Genentech | |
  4. 10.3.4 Bristol Myers Squibb | |
  5. 10.3.5 Johnson & Johnson | |
  6. 10.3.6 Eli Lilly | |
  7. 10.3.7 Amgen | |
  8. 10.3.8 Novartis | |
  9. 10.3.9 Pfizer | |
  10. 10.3.10 Takeda | |
  11. 10.3.11 Daiichi Sankyo | |
  12. 10.3.12 Boehringer Ingelheim
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Lung Cancer Therapeutics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Lung Cancer Therapeutics Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis – Estimated Contribution to CAGR, 2026–2035 |
TABLE 4 Restraint Impact Analysis – Estimated Drag on CAGR, 2026–2035 |
TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Disease Type, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by Treatment Modality, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 14 Global Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 15 Global Market Size, by Line of Therapy, 2021–2035 (USD Billion) |
TABLE 16 North America Market Size, by Disease Type and Treatment Modality, 2021–2035 (USD Billion) |
TABLE 17 Europe Market Size, by Disease Type and Treatment Modality, 2021–2035 (USD Billion) |
TABLE 18 Asia-Pacific Market Size, by Disease Type and Treatment Modality, 2021–2035 (USD Billion) |
TABLE 19 South America Market Size, by Disease Type and Treatment Modality, 2021–2035 (USD Billion) |
TABLE 20 Middle East & Africa Market Size, by Disease Type and Treatment Modality, 2021–2035 (USD Billion) |
TABLE 21 Competitive Benchmarking Matrix – Global Lung Cancer Therapeutics Market, 2026 |
TABLE 22 Company Profiles – Key Players, Global Lung Cancer Therapeutics Market |
TABLE 23 Recent Developments & Regulatory Milestones, 2023–2025 |
TABLE 24 Report Scope & Methodology Summary |
TABLE 25 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics – Drivers, Restraints and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis – Discovery to Dispensing |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend and Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Market Share by Disease Type, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Treatment Modality, 2025 vs 2035 (%) |
FIGURE 8 Market Share by Drug Class, 2025 vs 2035 (%) |
FIGURE 9 Market Share by Distribution Channel, 2025 (%) |
FIGURE 10 Market Share by Line of Therapy, 2025 (%) |
FIGURE 11 Regional Revenue Share Distribution, 2025 (%) |
FIGURE 12 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 13 North America Country-Level Share Breakdown, 2025 (%) |
FIGURE 14 Asia-Pacific Country-Level Growth Comparison, 2026–2035 (%) |
FIGURE 15 Competitive Landscape – Estimated Revenue Share Positioning, 2026 |
FIGURE 16 Regulatory Approval Timeline, 2023–2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Disease Type	Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Others	Non-Small Cell Lung Cancer	Small Cell Lung Cancer
By Treatment Modality	Chemotherapy, Immunotherapy, Targeted Therapy, Others	Chemotherapy	Immunotherapy
By Drug Class	Small-Molecule Drugs, Biologics and Biosimilars	Small-Molecule Drugs	Biologics and Biosimilars
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online / Specialty Pharmacies	Hospital Pharmacies	Retail Pharmacies
By Line of Therapy	First-Line, Second-Line, Third-Line and Later	First-Line	Third-Line and Later
By Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Disease Type

Sub-Segment	Key Trend
Non-Small Cell Lung Cancer	Perioperative and stage III label expansion pulling revenue into earlier disease.
Small Cell Lung Cancer	DLL3-directed bispecific approval ending a two-decade innovation gap
Others	Mesothelioma and rare thoracic tumours gaining dedicated trial attention

Disease type remains the primary axis of commercial differentiation because approved mechanisms map almost entirely onto histology. Non-small cell disease carries the volume and the biomarker diversity; small cell disease carries the growth rate.

By Treatment Modality

Sub-Segment	Key Trend
Chemotherapy	Repositioning as a combination backbone rather than a standalone regimen
Immunotherapy	Moving backward into neoadjuvant and adjuvant settings
Targeted Therapy	Expanding with each new actionable alteration and resistance-directed follow-on
Others	Radiopharmaceutical and supportive care agents entering thoracic protocols

Modality mix is shifting faster than headline shares suggest, because chemotherapy volume increasingly appears inside branded combination protocols rather than as generic monotherapy.

By Drug Class

Sub-Segment	Key Trend
Small-Molecule Drugs	Successive inhibitor generations sustaining oral franchise value
Biologics and Biosimilars	Antibody-drug conjugates and bispecifics driving above-market growth.

Class competition is converging: several developers now run parallel small-molecule and biologic programmes against the same target, hedging against both resistance and biosimilar entry.

By Distribution Channel

Sub-Segment	Key Trend
Hospital Pharmacies	Retaining infusion and monitoring-intensive agents
Retail Pharmacies	Capturing oral targeted therapy volume as prescriptions shift outward
Online / Specialty Pharmacies	Building adherence and home-delivery services around chronic oral dosing

Channel economics follow dosing format. Every oral approval moves a slice of revenue away from hospital dispensing toward specialty and retail networks.

By Line of Therapy

Sub-Segment	Key Trend
First-Line	Intensifying through chemotherapy-free and combination regimens
Second-Line	Driven by predictable resistance emergence on targeted agents
Third-Line and Later	Expanding as survival gains keep more patients eligible for further treatment

Line-of-therapy distribution is a direct readout of survival improvement. Longer survival deepens the funnel, and later-line growth will outpace first-line growth throughout the forecast period.

By Geography

Sub-Segment	Key Trend
North America	Price negotiation offsetting early-access revenue advantage
Europe	Joint clinical assessment standardising evidence review across member states
Asia-Pacific	National reimbursement listings converting high incidence into paid volume
South America	Tender-based public procurement alongside premium private segment
Middle East & Africa	Gulf oncology infrastructure investment outpacing regional averages.

Regional divergence now stems more from payer architecture than from clinical practice, which has largely converged around the same international guidelines.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”